Get the Stockscreener App
3.105
0.64%
-0.035
Atea Pharmaceuticals Inc stock is traded at $3.105, with a volume of 20,724.
It is down -0.64% in the last 24 hours and down -0.64% over the past month.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
See More
Previous Close:
$3.14
Open:
$3.14
24h Volume:
20,724
Relative Volume:
0.06
Market Cap:
$246.41M
Revenue:
$351.37M
Net Income/Loss:
$-174.01M
P/E Ratio:
-1.50
EPS:
-2.07
Net Cash Flow:
$-126.94M
1W Performance:
+7.22%
1M Performance:
-0.64%
6M Performance:
+15.13%
1Y Performance:
-10.34%
1-Day Range:
$3.10
$3.14
1-Week Range:
$2.895
$3.1684
52-Week Range:
$2.455
$4.02
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Name
Atea Pharmaceuticals Inc
Sector
Industry
Phone
857-204-8109
Address
225 FRANKLIN STREET, BOSTON
Compare AVIR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
3.105 | 249.18M | 351.37M | -174.01M | -126.94M | -2.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.02 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.69 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
543.75 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
795.45 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-10-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-18-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-25-20 | Initiated | Evercore ISI | Outperform |
| Nov-24-20 | Initiated | JP Morgan | Overweight |
| Nov-24-20 | Initiated | Morgan Stanley | Overweight |
| Nov-24-20 | Initiated | William Blair | Outperform |
View All
Atea Pharmaceuticals Inc Stock (AVIR) Latest News
What MACD signals say about Atea Pharmaceuticals Inc.July 2025 Breakouts & Verified High Yield Trade Plans - newser.com
How hedge fund analytics apply to Atea Pharmaceuticals Inc. stock - newser.com
Will Atea Pharmaceuticals Inc. stock go up soonJuly 2025 Selloffs & Free AI Powered Buy and Sell Recommendations - newser.com
How to recover losses in Atea Pharmaceuticals Inc. stockWeekly Gains Report & Weekly Watchlist for Hot Stocks - newser.com
Analyzing recovery setups for Atea Pharmaceuticals Inc. investorsJuly 2025 Short Interest & AI Powered Market Entry Ideas - newser.com
What’s the recovery path for long term holders of Atea Pharmaceuticals Inc.Weekly Stock Recap & Real-Time Market Sentiment Alerts - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for Atea Pharmaceuticals (NASDAQ:AVIR) - MarketBeat
What analysts say about Atea Pharmaceuticals Inc stockBearish Engulfing Patterns & Market-Leading Growth Rates - earlytimes.in
Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025 - GlobeNewswire
Why Atea Pharmaceuticals Inc. stock is a must watch in 2025July 2025 Snapshot & Daily Profit Focused Screening - newser.com
Market reaction to Atea Pharmaceuticals Inc.’s recent news2025 Historical Comparison & Precise Swing Trade Entry Alerts - newser.com
Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing - Bain Capital
Relative strength of Atea Pharmaceuticals Inc. in sector analysisEarnings Overview Summary & Free High Accuracy Swing Entry Alerts - newser.com
Does Atea Pharmaceuticals Inc. show high probability of rebound2025 Top Gainers & Smart Allocation Stock Tips - newser.com
Using portfolio simulators with Atea Pharmaceuticals Inc. includedLayoff News & Accurate Buy Signal Notifications - newser.com
Historical volatility pattern of Atea Pharmaceuticals Inc. visualizedPortfolio Update Report & Free Expert Verified Stock Movement Alerts - newser.com
What machine learning models say about Atea Pharmaceuticals Inc.Weekly Gains Summary & Community Verified Swing Trade Signals - newser.com
How to manage a losing position in Atea Pharmaceuticals Inc.July 2025 Trends & Weekly Return Optimization Alerts - newser.com
Voya Investment Management LLC Reduces Stock Position in Atea Pharmaceuticals, Inc. $AVIR - Defense World
What drives Atea Pharmaceuticals Inc stock priceInstitutional Buying Trends & Machine Learning Stock Picks, Daily - earlytimes.in
Atea Pharmaceuticals Inc Stock (AVIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atea Pharmaceuticals Inc Stock (AVIR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BERGER FRANKLIN M | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
506,497 |
| Duncan Barbara Gayle | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Polsky Bruce | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
95,206 |
| Adams Jerome M. | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Lucidi Bruno | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
112,750 |
| BERGER FRANKLIN M | Director |
Dec 10 '24 |
Sale |
2.85 |
359,606 |
1,023,475 |
451,897 |
2.36%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):